NASDAQ:TXMD - TherapeuticsMD Stock Price, Forecast & News

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

TherapeuticsMD Inc (NASDAQ:TXMD) posted its earnings results on Wednesday, November, 6th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.06. The firm earned $8.21 million during the quarter, compared to the consensus estimate of $8.05 million. TherapeuticsMD had a negative return on equity of 430.28% and a negative net margin of 427.70%. The company's quarterly revenue was up 136.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.16) EPS. View TherapeuticsMD's Earnings History.

TherapeuticsMD is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for TherapeuticsMD.

TherapeuticsMD will be holding an earnings conference call on Thursday, February 20th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

9 analysts have issued 12-month price targets for TherapeuticsMD's shares. Their forecasts range from $3.00 to $17.00. On average, they expect TherapeuticsMD's stock price to reach $9.11 in the next year. This suggests a possible upside of 267.4% from the stock's current price. View Analyst Price Targets for TherapeuticsMD.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TherapeuticsMD.

Media headlines about TXMD stock have trended somewhat positive recently, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. TherapeuticsMD earned a coverage optimism score of 1.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for TherapeuticsMD.

TherapeuticsMD saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 86,820,000 shares, an increase of 9.4% from the December 31st total of 79,360,000 shares. Based on an average daily volume of 3,670,000 shares, the days-to-cover ratio is currently 23.7 days. Approximately 36.6% of the shares of the stock are short sold. View TherapeuticsMD's Current Options Chain.

Some companies that are related to TherapeuticsMD include ArQule (ARQL), Biohaven Pharmaceutical (BHVN), Karuna Therapeutics (KRTX), Epizyme (EPZM), Ra Pharmaceuticals (RARX), Synthorx (THOR), Turning Point Therapeutics (TPTX), Prestige Consumer Healthcare (PBH), Principia Biopharma (PRNB), Aurinia Pharmaceuticals (AUPH), Pacira Biosciences (PCRX), Xencor (XNCR), Cambrex (CBM), Eidos Therapeutics (EIDX) and Esperion Therapeutics (ESPR).

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include Opko Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Cleveland-Cliffs (CLF), CannTrust (CNTTF), NVIDIA (NVDA), Horizon Therapeutics (HZNP), Inovio Pharmaceuticals (INO), bluebird bio (BLUE) and Global Blood Therapeutics (GBT).

TherapeuticsMD's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (6.52%), Bank of New York Mellon Corp (4.84%), Franklin Resources Inc. (3.50%), State Street Corp (2.04%), Stifel Financial Corp (1.11%) and Charles Schwab Investment Management Inc. (0.49%). Company insiders that own TherapeuticsMD stock include Angus C Russell, Brian Bernick, Daniel A Cartwright, Group L P Column, Jane F Barlow, John CK Iv Milligan, Jules A Musing, Robert G Finizio and Tommy G Thompson. View Institutional Ownership Trends for TherapeuticsMD.

TXMD stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Public Employees Retirement Association of Colorado, FMR LLC, Franklin Resources Inc., Sanders Morris Harris LLC, SG Americas Securities LLC, Raymond James & Associates and First Eagle Investment Management LLC. View Insider Buying and Selling for TherapeuticsMD.

TXMD stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Marshall Wace North America L.P., State Street Corp, Knights of Columbus Asset Advisors LLC, Goldman Sachs Group Inc., Stifel Financial Corp, Spark Investment Management LLC and Virtu Financial LLC. Company insiders that have bought TherapeuticsMD stock in the last two years include Angus C Russell, Brian Bernick, Group L P Column, Jane F Barlow, John CK Iv Milligan, Robert G Finizio and Tommy G Thompson. View Insider Buying and Selling for TherapeuticsMD.

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TXMD stock can currently be purchased for approximately $2.48.

TherapeuticsMD has a market capitalization of $672.53 million and generates $16.10 million in revenue each year. The company earns $-132,620,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. TherapeuticsMD employs 241 workers across the globe.View Additional Information About TherapeuticsMD.

The official website for TherapeuticsMD is http://www.therapeuticsmd.com/.

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The company can be reached via phone at 561-961-1900 or via email at [email protected]